therapeutics

Antibody Basics: Part 7 - Functions in the human body: Understanding the key roles of antibodies

Antibodies defend health by neutralizing pathogens, aiding phagocytosis, and activating complement. Biointron explains these vital functions in immunity and therapy.

Apr 27, 2024
Critical Reagents in Therapeutic Antibody Development: Why They Matter

Explore the role of anti-idiotype antibodies and critical reagents in therapeutic antibody development, ensuring specificity, potency, and safety in drug testing.

Apr 24, 2024
Antibody Basics: Part 6 - Antibody formats: Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates unite precision with potency. Biointron outlines how ADCs combine antibodies with cytotoxic drugs to deliver targeted cancer therapies.

Apr 19, 2024
Week 2, Apr 2024: Cancer Research Trends at AACR

Here at the AACR Annual Meeting 2024, there are over 7000 abstracts, 300 poster presentations, and 50 symposia all about cancer research. A few topics that are currently trending in the conference include cancer vaccines, AI for diagnostics, novel immunotherapies, and antibody-drug conjugates (ADCs) as a new modality.

Apr 11, 2024
Antibody Basics: Part 5 - Antibody Formats: Antibody fragments (Fab, F(ab')2, Fc)

Learn about Fab, F(ab')2, and Fc antibody fragments—how they are generated, their roles in antigen targeting, and their evolving applications in biomedical research and therapy.

Apr 10, 2024
Week 1, Apr 2024: The Complexities of Drug Approvals

The development and approval of novel antibody drugs represent a significant segment of pharmaceutical innovation, addressing a wide range of diseases from cancer to autoimmune disorders. Since the first monoclonal antibody (mAb) drug was approved in 1986, there has been explosive growth in this area. By 2021, the US FDA had approved its 100th mAb product, with mAbs now accounting for nearly a fifth of the agency’s new drug approvals each year.

Apr 02, 2024
Bispecific Antibodies: Design, Development, and Therapeutic Potential

Bispecific antibodies are transforming medicine. Biointron highlights their design, therapeutic applications, and development pathways for next-generation therapies.

Mar 29, 2024
Week 3, Mar 2024: Organ Transplantation

This week, exciting news came out that Eledon Pharmaceuticals’ tegoprubart was successfully used to aid the first-ever transplant of a genetically-edited pig kidney into a 62-year-old man with end-stage kidney disease. Tegoprubart is an investigational anti-CD40L antibody that has a high affinity for CD40 ligand. CD40L signaling plays an important role in adaptive and innate immune cell activation and function, and is therefore a target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.

Mar 26, 2024
The Role of CROs in Accelerating Therapeutic Development

Discover how Contract Research Organizations (CROs) accelerate therapeutic development through specialized expertise, cost-effective solutions, scalability, and biotech innovation.

Mar 22, 2024
Understand Single B Cell Antibody Technology in One Read

Single B cell technology accelerates antibody discovery. Biointron demonstrates how this approach delivers potent candidates faster and with greater precision.

Mar 15, 2024
Week 2, Mar 2024: The Battle Against Cancer

Image credit: DOI: 10.3390/cancers16040800 In recent decades, the landscape of therapeutic antibodies has undergone a rapid evolution, catalyzing breakthroughs in modern medicine. These antibodies, characterized by their precise targeting and minimal side effects

Mar 12, 2024
Week 1, Mar 2024: Antibodies and Nucleocapsid Proteins

The nucleocapsid of a virus, which consists of the capsid enclosing the viral nucleic acid, can be a target for antibody therapies. When a virus infects a host, its nucleocapsid becomes exposed to the immune system, triggering the production of antibodies specific to proteins present on the nucleocapsid's surface, preventing the virus from entering host cells, disrupting its replication cycle, or marking it for destruction by other components of the immune system.

Mar 06, 2024
February 2024: Antibiotic antibodies, antibiotic conjugates, and antimicrobials!

In the realm of combating bacterial infections and antimicrobial resistance, antibodies are beginning to stand out as a therapy with innovative strategies and engineering methods continually being published. This month’s trend will focus on the developments in ‘antibiotic antibodies’, antibody-antibiotic conjugates, and antibody antimicrobials, which are particularly important for immunocompromised patients.

Mar 05, 2024
Demystifying Agonist Antibodies: Mechanisms and Future Views

Explore agonist antibodies, their receptor-activating mechanisms, immune-modulating effects, and emerging therapeutic potential in cancer and autoimmune diseases.

Mar 04, 2024
Week 4, Feb 2024: Antibodies for Toxins

Toxins are substances produced by living organisms, such as bacteria, fungi, plants, and animals, that are harmful to other organisms. Antibodies play a crucial role in immune responses for the body's defense against toxin intoxication, in addition to being invaluable tools for both diagnostic and therapeutic applications.

Feb 29, 2024

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.